SunTrust Robinson Humphrey Downgrades Summit Therapeutics plc (SMMT) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
Summit Therapeutics plc (SMMT) PT Lowered to $3 at H.C. Wainwright
June 29, 2018 7:11 AM EDTH.C. Wainwright lowered its price target on Summit Therapeutics plc (NASDAQ: SMMT) to $3.00 (from $20.00) while maintaining a Buy rating.
... MoreSummit Therapeutics plc (SMMT) PT Lowered to $5 at BTIG
June 27, 2018 2:21 PM EDTBTIG lowered its price target on Summit Therapeutics plc (NASDAQ: SMMT) to $5.00 (from $33.00) while maintaining a Buy rating.
Analyst Tim Chiang comments " We have made significant revisions to our model and have removed ezutromid. With SMMT shares down ~80% intraday, the shares are now... More
Oppenheimer Downgrades Summit Therapeutics plc (SMMT) to Perform
June 27, 2018 2:20 PM EDTOppenheimer downgraded Summit Therapeutics plc (NASDAQ: SMMT) from Outperform to Perform.
For an analyst ratings summary and ratings history on Summit Therapeutics plc click here. For more ratings news on Summit Therapeutics plc click here.
Shares of Summit Therapeutics plc closed at $12.65 yesterday.
... MoreSummit Therapeutics (SMMT) to Resumes Trading at 7:30 am ET
June 27, 2018 7:11 AM EDTSummit Therapeutics (NASDAQ: SMMT) to Resumes Trading at 7:30 am ET
... MoreSummit Therapeutics (SMMT) Says PhaseOut DMD Did Not Meet Primary Endpoint; Company is Discontinuing Development of Ezutromid
June 27, 2018 7:01 AM EDT(Updated - June 27, 2018 7:02 AM EDT)
Summit Therapeutics plc (NASDAQ: SMMT) today announces PhaseOut DMD has not met its primary or secondary endpoints after 48 weeks of treatment of ezutromid in patients with Duchenne muscular dystrophy (DMD). PhaseOut DMD was a multi-centre, open-label Phase 2 clinical trial of the utrophin modulator, ezutromid.
Based on this outcome, the Company is discontinuing its... More
